MapLight Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
800 Chesapeake Dr, Redwood City, Califor...Phone Number
(617) 984-6300Website
www.maplightrx.comRevenue
-Industry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. MapLights discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.Explore more
MapLight Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MapLight Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on MapLight Therapeutics recently announced quarterly report
Check if MapLight Therapeutics has recently received funding, and reach out quickly before it becomes old news!
MapLight Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if MapLight Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once MapLight Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MapLight Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at MapLight Therapeutics
Check out if MapLight Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MapLight Therapeutics
Compare insights from companies similar to MapLight Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MapLight Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MapLight Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MapLight Therapeutics.
MapLight Therapeutics financials insights
Gather financial insights about MapLight Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series C
$225M
2025
Multiple Rounds
$819.6M
MapLight Therapeutics Tech Stack
A closer look at the technologies used by MapLight Therapeutics
Most Recent Scoops
Project
MapLight Therapeutics has announced plans to request an end-of-phase 2 meeting with the FDA following a full data review of the IRIS trial, with the regulatory pathway for irritability in autism spectrum disorder already established through prior approvals of aripiprazole and Risperdal using the ABC-I scale as the primary endpoint the same scale used in IRIS.
Clinical Operations
Project
reported three key safety observations in the adolescent population from the IRIS trial: mean weight gain of 1.1 kilograms with ML004 versus 1.9 kilograms with placebo, a placebo-adjusted somnolence rate of 11.8%, and no extrapyramidal events observed, consistent with the mechanism of action of ML004.
Project
reported that in the pre-specified adolescent subgroup with clinically significant baseline irritability, ML004 demonstrated a mean change from placebo of 7.2 points and an effect size of 1.0 at approximately 7 weeks of maintenance dosing, increasing to an LS mean difference of 9.6 points with an effect size of 1.33 and a nominally statistically significant p-value by the end of the 12-week maintenance period, with the growing separation over time considered biologically consistent with the mechanism of action.
Medical Research
Person-Based
Medical Research
Person-Based
Medical Research
MapLight Therapeutics News & Media
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder June 22, 2026 8:00 AM EDTCompany...MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder (ASD). The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses planned by age group and baseline irMapLight Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treat
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MapLight Therapeutics
Sign Up For FreeTo access detailed company insights
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.... Read More
